NordicCan A/S has filed a patent application for a cannabinoid lozenge formulation, which may offer enhanced bioavailability and targeted delivery of cannabinoids. The claimed invention involves a specific combination of excipients and APIs to create a lozenge that can be easily administered orally. This novel formulation could potentially address issues with traditional cannabis products.
Clinical Perspective & Therapeutic Significance
Novel cannabinoid delivery systems offer potential advantages in bioavailability and standardized dosing.
Intellectual Property & Market Landscape
This patent application reflects ongoing intellectual property investment by NordicCan A/S.
“”This novel lozenge formulation has the potential to improve cannabinoid bioavailability and targeted delivery, which could lead to enhanced therapeutic efficacy in various conditions.””
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
